These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27354764)

  • 21. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.
    Lymperopoulos A; McCrink KA; Brill A
    Curr Drug Metab; 2015; 17(1):30-6. PubMed ID: 26537419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6.
    Narimatsu S; Kato R; Horie T; Ono S; Tsutsui M; Yabusaki Y; Ohmori S; Kitada M; Ichioka T; Shimada N; Kato R; Ishikawa T
    Chirality; 1999; 11(1):1-9. PubMed ID: 9914647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 24 CYP2D6 variants found in Chinese population on the metabolism of clonidine in vitro.
    Li XY; Hu XX; Yang F; Yuan LJ; Cai JP; Hu GX
    Chem Biol Interact; 2019 Nov; 313():108840. PubMed ID: 31585114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double site saturation mutagenesis of the human cytochrome P450 2D6 results in regioselective steroid hydroxylation.
    Geier M; Braun A; Fladischer P; Stepniak P; Rudroff F; Hametner C; Mihovilovic MD; Glieder A
    FEBS J; 2013 Jul; 280(13):3094-108. PubMed ID: 23552177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine.
    Xu RA; Gu EM; Zhou Q; Yuan L; Hu X; Cai J; Hu G
    Drug Des Devel Ther; 2016; 10():687-96. PubMed ID: 26937172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
    Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
    Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae.
    Hanioka N; Okumura Y; Saito Y; Hichiya H; Soyama A; Saito K; Ueno K; Sawada J; Narimatsu S
    Biochem Pharmacol; 2006 Apr; 71(9):1386-95. PubMed ID: 16527257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro.
    Weng Q; Liang B; Zhou Y; Li X; Wang H; Zhan Y; Dai D; Cai J; Hu G
    Pharm Biol; 2016 Nov; 54(11):2475-2479. PubMed ID: 27097346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
    Yu A; Kneller BM; Rettie AE; Haining RL
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
    Dehal SS; Kupfer D
    Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol.
    Iwaki M; Niwa T; Bandoh S; Itoh M; Hirose H; Kawase A; Komura H
    Drug Metab Pharmacokinet; 2016 Dec; 31(6):425-432. PubMed ID: 27836712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
    Shen HW; Wu C; Jiang XL; Yu AM
    Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional characterization of 22 novel CYP2D6 variants for the metabolism of Tamoxifen.
    Hu XX; Zhou Q; Lan T; Huang XX; Liang BQ; Dai DP; Cai JP; Hu GX
    J Pharm Pharmacol; 2016 Jun; 68(6):819-25. PubMed ID: 27109434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
    Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
    Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics and heart failure: a convergence with carvedilol.
    Meadowcroft AM; Williamson KM; Patterson JH; Pieper JA
    Pharmacotherapy; 1997; 17(4):637-9. PubMed ID: 9250542
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
    Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
    Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Human Cytochrome P450 2D6 Polymorphism on Progesterone Hydroxylation.
    Niwa T; Sasaki S; Yamamoto Y; Tanaka M
    Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):741-747. PubMed ID: 35838883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.
    Takekuma Y; Takenaka T; Yamazaki K; Ueno K; Sugawara M
    Biol Pharm Bull; 2007 Nov; 30(11):2146-53. PubMed ID: 17978490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
    Ur Rasheed MS; Mishra AK; Singh MP
    Neurochem Res; 2017 Dec; 42(12):3353-3361. PubMed ID: 28871472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
    Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
    J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.